About Us

NimbinCann is an Australian “seed to shelf” medical cannabis company which plans to produce pharmaceutical-grade cannabis products in a variety of forms and supply it to the Australian and global pharmaceutical industries and directly to patients. NimbinCann will operate at least two medical cannabis cultivation and manufacturing facilities – in Australia and Thailand. The facilities will run as fully-integrated businesses with the core processes maintained in-house. The business will utilize intensive growing methods aiming to achieve four to growing cycles a year. It will also focus on research and development activities to develop own cannabis flower varieties. NimbinCann will initially target medicinal cannabis users in Australia. As the business develops, a network of retail dispensaries will be launched throughout Australia and Thailand, selling genuine NimbinCann medical cannabis products directly to patients. Long term, NimbinCann’s cannabinoid compounds’ distillates and isolates will be supplied to manufacturers in North America and Europe, and its pharmaceutical, nutraceutical and cosmeceutical retail products to retailers and distributors in Europe and Asia. NimbinCann is being set up by a team of successful entrepreneurs, experienced business executives and cannabis industry experts – Richard Duce, David Evans and Chris Waldron. They have been involved in the Australian and global cannabis industries for many years and can see substantial gaps in supply of quality medicinal cannabis products on the market, in particular in Australia. The founders want to establish NimbinCann as a premier Australia supplier of medicinal cannabis known as a consistent, easily accessible and affordable source of high-quality medical cannabis.

Meet The Team

Richard Duce

Richard Duce

Managing Director

Is an experienced acquisition, project and sales manager with over 20 years in the Australian property development industry. Over the last 10 years he has been working as Acquisition & Project Manager at Leda Holdings, a property development company with large commercial, retail and residential portfolios in NSW, Qld and the ACT. Richard has been studying and monitoring the global cannabis industry for over 20 years; he got his first US medical cannabis licence in 2009 in Venice Beach, CA, and again in 2014. Richard holds Associate Diploma in Business..

David Evans

David Evans

Director, Australia Business Development & Operations

Is an experienced business executive and medical cannabis entrepreneur with over 26 years of experience in Australia and globally.  David founded, developed and successfully floated on the ASX a number of mining and cannabis companies, including backdoor listing Medical Cannabis Ltd (now part of Cann Global Limited, ASX: CGB). He is also a co-founder and major shareholder of Cann Global Thailand Pty Ltd, Cann Global Asia Pty Ltd and Biorefine Pty Ltd. He has worked in the stock broking industry as both mining analyst and dealer and in the mining industry as a geologist. David holds a Bachelor of Science degree.

Chris Waldron

Director, Thailand Business Development & Operations

Is an experienced business executive. He has been closely involved in the medical cannabis industry development in South-East Asia from 2017 and currently works as Operations Manager at Cann Global Asia and Cann Global Thailand. Chris has over 30 years of experience in IT, working in positions such as Director of IT Service at the Australian Department of the Treasury and Senior Manager of the IT Directorate at the Organisation of Economic Co-operation and Development (OECD). Chris holds Bachelor of Science degree.

Major Partners in Australia

To expedite the launch of the Australian operations, the business has partnered with CannaPacific, a licenced Australian medicinal cannabis producer. CannaPacific will grow white label dry flowers for NimbinCann and assist with the ODC application process, R&D activities and development of the site.
Additionally, NimbinCann has engaged Pharmout, a leading GMP consultant to manage the compliance processes, including the ODC and TGA progression.
NimbinCann is in talks with Southern Cross University’s Associate Professor Bronwyn Barkla, Director of Plant Science, to do medicinal cannabis research once the ODC research licence is approved.
Planit Consulting, a development consulting company providing services from concept to construction, is engaged as the principal project manager for the NimbinCann’s Australian facility

Thailand Operations

The Thailand facility is being established by NimbinCann Thailand (NimbinCann Co. Ltd), a subsidiary of NimbinCann Pty Ltd, which will operate as a “seed to shelf” commercial cannabis and hemp business. NimbinCann Thailand is applying for its own commercial hemp licences and expects to obtain them by the 1st September 2021.
NimbinCann Thailand will use its Thai partners’ Green Pharma Botanical & Akira Natural) cannabis licences to start cannabis cultivation on the 1st July 2021, depending on the availability of investment capital. The first 281 kg of CBD oil will be produced in approximately seven months after the launch. NimbinCann Thailand will also apply for its own commercial cannabis licences once the new regulation are released later this year.
Given a significant shortage of quality medicinal cannabis products on the Australian market, the Thailand business will apply to export part of its output to Australia where it will be wholesaled through the NimbinCann Australia medicinal cannabis import licence and/or CannaPacific licences.